<< Back Somatostatin Analogue (SSA) CAREFNDR: Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen Paltusotine in Carcinoid Syndrome SORENTO™: Subcutaneous Octreotide for GEP-NETs LAMPARA: LAnreotide in Metastatic Pheochromocytoma/PARAganglioma

<< Go back to the Podcast page EPISODE 39: NEN TREATMENTS: FOCUS ON LIVER-DIRECTED THERAPIES PART II: Intra-Arterial Techniques and Sequencing Download a Transcript of this Episode >>> ABOUT THIS EPISODE In this 2-part series, Dr. Osman Ahmed from University of Chicago covers liver-directed therapies for neuroendocrine neoplasms (NENs or neuroendocrine cancer). In this second episode, he details the embolization techniques including bland embolization (TAE), chemoembolization (TACE), and radioembolization (TARE, SIRT, y90). He discusses decision-making, sequencing, and follow-up after these procedures. MEET DR. OSMAN AHMED Osman Ahmed, MD, is an expert vascular and interventional radiologist who diagnoses and treats a wide range of conditions. Using image-guided technology and small, sophisticated instruments, Dr. Ahmed performs minimally invasive procedures for acute and chronic deep vein thrombosis, benign prostatic hyperplasia, peripheral vascular disease, liver/bone/lung/kidney cancer, spinal fractures, uterine fibroids and more. He also implants inferior vena cava (IVC) filters, which prevent a blood clot from traveling around the body or creating a blockage. In addition to his clinical expertise, Dr. Ahmed researches novel treatment options that improve outcomes for patients. His research on liver cancer, IVC filters and venous diseases has been published in several high-impact, peer-reviewed journals, including the Journal of Vascular and Interventional Radiology, Radiology, Chest, Journal of American College of Radiology, and Journal of Surgical Oncology. Dr. Ahmed also believes in the importance of educating medical students, residents, fellowships and peers in order to enhance health care across the world. He has been invited to speak at a number of symposiums, practicums and national/international meetings about the newest advancements in interventional radiology. TOP TEN QUESTIONS ABOUT LIVER-DIRECTED THERAPY, INCLUDING INTRA-ARTERIAL TECHNIQUES & SEQUENCING: What do patients need to know about bland embolization (TAE)? a. What are the possible side effects? b. How do the size of beads play a role? c. When is this recommended? d. Do you always do both sides of the liver? If so, what is the timing and why? e. What is the recovery like? What is post-embolization syndrome? What do patients need to know about chemoembolization (TACE)? a. What drug is used & does this go through the whole body? b. What is the recovery like? What are the possible side effects? What do patients need to know about radioembolization (TARE, SIRT, y90)? a. In the era of PRRT, is there a concern with using y90 or radioembolization? How is the approach and techniques used with radioembolization different than how it was done in the past? Is there a total lifetime limit of radiation? b. What is the recovery like? What are the possible side effects? Is there a limit to how much LDT one can do? Can they be repeated? How does one decide between the various types of liver-directed therapies? Is there a sequencing to treatments? Are there certain treatments that make you ineligible for other treatments? [PRRT, chemo, y90 etc] If someone has had surgery such as a Whipple or surgery or procedures involving the bile duct such as a stent in the bile duct or surgical removal of part of the bile duct, how does this weigh into the decision-making process for LDT? How do you determine if the treatment “worked?” What is the follow up like? What scan might you do and in what timing? What do you see as the future of liver-directed therapy in neuroendocrine cancer treatment? RESOURCES LISTEN Episode 38: NEN Treatments: Focus on Liver-Directed Therapies (Part I: Overview and Ablative Techniques Including Histotripsy) WATCH LACNETS Liver-Directed Therapy Videos DISCLAIMER LACNETS Podcasts are created for educational purposes only and do not substitute for medical advice. The views shared in this Podcast are the personal opinions of the experts and do not necessarily reflect the views of LACNETS. Please contact your medical team with questions or concerns about your individual care or treatment. THANK YOU TO OUR SPONSORS

<< Go back to the Podcast page EPISODE 34: NET TREATMENTS: FOCUS ON PRRT Download a Transcript of this Episode >>> ABOUT THIS EPISODE What is PRRT? How is it different from the more commonly used radiation treatment? What are the possible side effects? Dr. Riham El Khouli from the University of Kentucky in Lexington discusses common questions and concerns about PRRT and shares some of the latest advances. MEET DR. RIHAM EL KHOULI, MD, PHD Associate Professor of Radiology, UK College of Medicine Chief, Division of Nuclear Medicine/Molecular Imaging & Radiotheranostics (NM/MI&R) Director, Radiotheranostics Program University of Kentucky Dr. Riham El Khouli, MD PhD, is the director of the Radiotheranostics program and Chief of the division of NM/MI&R at the University of Kentucky and an Associate Professor of Radiology, Nuclear Medicine and Molecular Imaging at UK school of Medicine. The Radiotheranostics Program at UK is a multidisciplinary program that provides state of art standard of care clinical radiopharmaceutical therapy (RPT) techniques as well as a robust research program that constantly runs multiple RPT clinical trials aiming to explore new RPT management options for various cancers. Dr. El Khouli is fellowship trained double board certified, ABR and ABNM, academic Nuclear Radiologist with two decades of clinical and research experience. Her research initially focused on the evaluation and improvement of the acquisition and interpretation of advanced MRI techniques such as dynamic contrast enhanced (DCE) MRI, Diffusion weighted imaging (DWI), and 1H MR Spectroscopy in breast cancer. On 2013, Dr. El Khouli started a new journey in Nuclear Medicine, Molecular Imaging and Radioheranostics (NM/MI&R) and completed a nuclear medicine and dedicated PET/CT fellowships. During her new training, her passion toward molecular imaging and PET/CT grew and she participated in multiple nuclear medicine and PET/CT related research projects. Dr. El Khouli is passionate about research and education and active in the field of neuroendocrine tumor. She is one of the key team members of the dedicated biweekly intramural NET tumor boards. She also attended and presented in multiple regional NANETS and NET awareness group meetings (NCAN). Dr. El Khouli serves as a peer reviewer for multiple prestigious Journals such as Radiology and Radiographics, among others, and is an active member of the Radiologic Society of North America (RSNA), Society of Nuclear Medicine and Molecular Imaging (SNMMI), and the American College of Radiology (ACR). She serves as an active member of the RSNA Awards Committee, RSNA Scientific Abstract Review Committee, and Radiographic NMMI review panel committee. Dr. El Khouli is an active panel member of multiple ACR Appropriateness Criteria Panels. TOP TEN QUESTIONS ABOUT NET TREATMENTS: What is PRRT? How does it work? What is theranostics and what does it mean? What are the terms radiotheranostics, radiopharmaceutical, radioligand therapy, PRRT? How do you determine who is eligible for PRRT? When is PRRT given in one’s treatment journey? How does PRRT differ from other treatments? What are the common side effects of Lutathera? Does Lutathera have long-lasting effects? Would receiving Lutathera affect one’s blood counts? How might Lutathera affect one’s liver function? When, if ever is there concern about liver failure? How might PRRT affect my quality of life and my day-to-day ability to work and function? What is the risk and effects of radiation with receiving Lutathera? What precautions do I need to follow? Can I hug my child? Can I pet my dog? Would receiving Lutathera cause someone to be immunocompromised? How to you decide who should get PRRT? What is peritoneal disease and how effective is PRRT with peritoneal disease? How do you assess the response to PRRT? What advances in PRRT are you most excited about? RESOURCES PRRT Clinical Trials PRRT Resources WATCH https://www.youtube.com/watch?v=oSqUgq6QdnM May 2024 LACNETS Educational Event with Dr. Aman Chauhan: "High Grade Neuroendocrine Neoplasms & Small Cell Lung Cancer" DISCLAIMER LACNETS Podcasts are created for educational purposes only and do not substitute for medical advice. The views shared in this Podcast are the personal opinions of the experts and do not necessarily reflect the views of LACNETS. Please contact your medical team with questions or concerns about your individual care or treatment. THANK YOU TO OUR SPONSORS

CDK4/6 Abemaciclib GEP-NETS << Back Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors CLINICALTRIALS.GOV IDENTIFIER: NCT03891784 DRUG/TREATMENT: abemaciclib PHASE: 2 STATUS: Recruiting SPONSOR: University of Washington Collaborator: Eli Lilly and Company https://www.youtube.com/watch?v=nzR8G_0DLQo Dr. Heloisa Soares Discusses CDK4/6 abemaciclib GEP-NETS DESCRIPTION: This phase II trial studies how well abemaciclib works in treating patients with digestive system neuroendocrine tumors that have spread to other places in the body, do not respond to treatment, and cannot be removed by surgery. Abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here. CONTACT/Principal Investigator: David B. Zhen, MD Fred Hutch/University of Washington Cancer Consortium EMAIL : dbzhen@uw.edu

Lu-177 DOTATATE vs Everolimus in Lung NETs << Back Randomized Phase II Trial of Lutetium Lu-177 Dotatate Versus Everolimus in Somatostatin Receptor Positive Bronchial Neuroendocrine Tumors DRUG/TREATMENT: LUTETIUM LU-177 DOTATATE (PRRT) + (EVEROLIMUS) CLINICALTRIALS.GOV IDENTIFIER: NCT04665739 PHASE: 2 STATUS: Recruiting SPONSOR: National Cancer Institute (NCI) https://www.youtube.com/watch?v=v8Ev1_8DVdo Dr. Suki Padda Discusses Lu177 Dotatate in Lung NETs https://www.youtube.com/watch?v=Z6ky87smo-I Dr. Heloisa Soares Discusses Lu-177 Dotatate in Lung NETs DESCRIPTION: This phase II trial studies the effect of lutetium Lu-177 dotatate compared to the usual treatment (everolimus) in treating patients with somatostatin receptor positive bronchial neuroendocrine tumors that have spread to other places in the body (advanced). Radioactive drugs, such as lutetium Lu-177 dotatate, may carry radiation directly to tumor cells and may reduce harm to normal cells. Lutetium Lu-177 dotatate may be more effective than everolimus in shrinking or stabilizing advanced bronchial neuroendocrine tumors. For more information on eligibility criteria, trial locations, study details, etc. go to ClinicalTrials.gov to view this trial here. PRINCIPAL INVESTIGATORS: Thomas A. Hope, MD, UCSF Sukhmani K. Padda, MD, Cedars Sinai Medical Center, Los Angeles, California CONTACT: This is a multicenter trial with various locations. Go to the “Contacts and Locations” section of this trial page at ClinicalTrials.gov for site-specific contact information.

Neuroendocrine Cancer Foundation Upcoming Patient & Caregiver Events "Practical Tips in Managing Your Neuroendocrine Cancer Care" Virtual Sep 29, 2026, 10 - 11:30 AM Pacific Join Taymeyah and Tiffany as they share important insights to help you spearhead your medical team and confidently navigate your healthcare. Gain practical logistics for managing the ongoing cycle of scans, lab work, and "ologist" appointments. Discover well-informed, real-world suggestions on finding and building strong partnerships with your providers and specialists. We hope this discussion empowers you to effectively and efficiently coordinate your care. Watch "Luncheon With The Experts" With Dr. Mintallah Haider October 22, 2026, Noon - 1 PM Eastern (9 AM Pacific) “Luncheon With The Experts” is a recurring educational opportunity (previously hosted by the Carcinoid Cancer Foundation) that connects patients and caregivers with extraordinary experts in neuroendocrine cancer. The sessions are hosted by Rain Bennett. Join on October 22nd and drop your questions for Dr. Haider to answer in the comments on Facebook or chat on YouTube. Join 2026 NET Cancer Day Symposium Las Vegas, NV Nov 8, 2026 8:30 am - 3 pm The 2026 NET Cancer Day Symposium will bring the neuroendocrine cancer community together in Las Vegas, Nevada for a day of education, connection, and awareness. Register Neuroendocrine Tumor (NET) Patient & Caregiver Support Group Weekly on Wednesdays Oct. 7, 14, 21, 28, 2026 We provide a welcoming space to come together virtually for knowledge sharing and community support. The focus of the meeting is to connect with others living with, or supporting someone living with, neuroendocrine cancer. Both patients & caregivers discuss treatments, symptoms, living well and information uniquely related to this disease. This group is open to NET patients and caregivers. Register Neuroendocrine Tumor (NET) Caregiver Support Group Typically on the Last Saturday of the Month Upcoming Dates: Sept. 19, 2026 Oct. 24, 2026 Nov. 21, 2026 (to be confirmed) Dec. 19, 2026 Neuroendocrine Cancer Foundation's Monthly NET Caregiver-Only support group is a virtual space to come together for support, connection and community with other care partners who support, or have supported, those with Neuroendocrine Cancer. Unlike our Weekly Wednesday Support Group for Caregivers & Patients that focuses on medical aspects of NETs, this group focuses on the unique experiences and psycho-social concerns of caregivers. *OPEN TO NET CAREGIVERS ONLY. Register Click here for recent events

Speak with trained support specialists for guidance, resources, and compassionate assistance for neuroendocrine cancer patients and caregivers. Neuroendocrine Cancer Support Line The Neuroendocrine Cancer Foundation is here to help you and those affected by neuroendocrine cancer. If you are looking for more specific information than you have found on our resources page or virtual support offerings, please complete the following questionnaire* so we can provide more personalized support. Please allow us up to three business days to respond. We highly recommend reviewing and completing our NET VITALS tool to learn and share the most critical information about your or your loved one's NET diagnosis. *Please note, all patient information is kept strictly confidential and is only used to provide relevant resources. SUPPORT LINE QUESTIONNAIRE Scroll up after clicking 'submit' The Neuroendocrine Cancer Foundation does not substitute for medical advice, diagnosis, treatment or other healthcare services. The Neuroendocrine Cancer Foundation may provide information and connections to physicians, products, services, clinical trials or treatments related to neuroendocrine cancer, but the Neuroendocrine Cancer Foundation neither recommends nor endorses any particular healthcare institution or provider. Please consult your medical team about your individual care or treatment.

<< Go back to the Podcast page EPISODE 22: WHAT TO KNOW ABOUT PANCREATIC NETS Download a Transcript of this Episode >> ABOUT THIS EPISODE What is the difference between Pancreatic Neuroendocrine Tumor (PNET) and Pancreatic Cancer? Where exactly is the pancreas located and why is the tumor location important? NET Oncologist Dr. Jennifer Chan from Dana-Farber Cancer Institute takes us through how some treatments, imaging and blood work are unique to PNETs. She also expounds on several ongoing and active trials. MEET DR. JENNIFER CHAN Jennifer Chan, MD, MPH is an Associate Professor of Medicine at Harvard Medical School and Institute Physician in the Division of Medical Oncology at Dana-Farber Cancer Institute in Boston, MA. She focuses her clinical practice on the care of patients with neuroendocrine tumors and gastrointestinal cancers. Dr. Chan is the Director of the Program in Neuroendocrine and Carcinoid Tumors and Clinical Director for the Gastrointestinal Cancer Center at the Dana-Farber/Brigham and Women's Cancer Center. She has been principal investigator of multiple clinical trials investigating novel therapies for neuroendocrine tumors and has been involved in studies examining factors associated with clinical outcomes in patients with neuroendocrine tumors. Dr. Chan is a past chair of the Guidelines Committee of the North American Neuroendocrine Tumor Society (NANETS) and serves on the National Comprehensive Cancer Network (NCCN) Neuroendocrine Tumors Guidelines Panel. She is a member of the Neuroendocrine Tumor Taskforce of the National Cancer Institute and the Board of Directors of NANETS. TOP 10 QUESTIONS 1. What are pancreatic NETs? Where are they located? 2. How are pancreatic NETs found? What are the symptoms of a pancreatic NET? 3. How is pancreatic NETs different from “pancreatic cancer?” How is it different from a pancreatic cyst? 4. What types of labs, scans, or testing is done to determine if someone has a pancreatic NET? 5. What are some ways that pancreatic NETs differ from other types of NETs? What makes it unique? 6. How do you decide if the pancreatic NET can be surgically removed? What type of surgeon would make that determination? 7. How are pancreatic NETs treated medically (or nonsurgically)? How are treatments sequenced? 8. How are the treatments different from other NETs? 9. How are pancreatic NETs monitored? What types of bloodwork or tests should be done and how often should they be done? What is the best type of scan for pancreatic NETs? 10. What are clinical trials we should be aware of or exciting new treatments in the pipeline for pancreatic NETs? RESOURCES https://www.youtube.com/watch?v=2H_SChk3gxw "CABINET Trial - Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors Video Introduction" - Jennifer Chan https://www.youtube.com/watch?v=HHtDAQzDj9E "Update on NET Clinical Trials" with Dr. Heloisa Soares (Recorded March 10, 2023) https://www.youtube.com/watch?v=ozTjElpHiyQ "NET Medical Therapies & Clinical Trials" with Dr. Reidy-Lagunes - LACNETS 2022 LACNETS Annual Conference (Recorded June 18, 2022 ) https://www.youtube.com/watch?v=sZIVip3CIxI Systemic Therapy: GI, Lung, PNETS & Unknown Primary" - LACNETS 2020 Virtual NET Conference ( Recorded June 20, 2020 ) https://www.youtube.com/watch?v=u9-iTXz8G2Y NET Patient Mary's Story https://www.youtube.com/watch?v=ncemqQ_vhMI NET Patient Tom's Story https://www.youtube.com/watch?v=Mm7tQpqoxBU NET Caregiver Gilda's Story https://www.youtube.com/watch?v=aZtVzVO-JO0 NET Patient Federico's Story LISTEN LACNETS Podcast Episode 5: "Treatment for NETs" with Dr. Randy Hecht LACNETS Podcast Episode 7: "Imaging of NETs" with Dr. Gary Ulaner LACNETS Podcast Episode 11: "Pathology for NETs" with Dr. Sue Chang LACNETS Podcast Episode 19: "Beyond the Basics: The Pathology of NET" with Dr. Andrew M. Bellizzi NETWise Podcast Episode 10: Pancreatic NETs + Take the Quiz READ 2020 The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Pancreatic Neuroendocrine Tumors 2020 The North American Neuroendocrine Tumor Society Consensus Paper on the Surgical Management of Pancreatic Neuroendocrine Tumors CABINET Trial - Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors DISCLAIMER LACNETS Podcasts are created for educational purposes only and do not substitute for medical advice. The views shared in this Podcast are the personal opinions of the experts and do not necessarily reflect the views of LACNETS. Please contact your medical team with questions or concerns about your individual care or treatment. THANK YOU TO OUR SPONSORS

See videos of recent educational events on various topics on neuroendocrine cancer Recent Events When Hormones Interfere With Quality of Life in Neuroendocrine Cancers August 27, 2026, 1:30 - 3 PM Pacific Join Dr. Jaydira Del Rivero, medical oncologist and endocrinologist at the National Cancer Institute, for a discussion on how hormones can affect quality of life in people living with neuroendocrine cancer. Topics will include thyroid disorders, hormone-related side effects from immunotherapy, hormone replacement therapies, GLP-1 medications, and practical considerations for managing hormone-related symptoms and concerns. Watch Living With Neuroendocrine Cancer: The Caregiver/Co-Survivor Perspective July 30, 2026 Join us for an open and honest conversation with four individuals who support and care for loved ones living with neuroendocrine cancer as they share the realities of navigating a parallel journey as a caregiver. Watch Team Craig Fundraiser Benefitting Neuroendocrine Cancer Foundation Denver, Colorado July 1, 2026, 6 - 10 PM Mountain Team Craig chose the Neuroendocrine Cancer Foundation (NCF) to support its work on behalf of patients and families affected by neuroendocrine cancer. Read More 2026 Annual Patient Conference June 20, 2026 Watch the Virtual 2026 Neuroendocrine Cancer Patient Conference, a free online event designed for individuals living with neuroendocrine cancer, as well as caregivers and families seeking trusted, expert-led information. Watch "Luncheon With The Experts" with Dr. Jason Starr May 28, 2026 “Luncheon With The Experts” is a recurring educational outreach series (previously hosted by the Carcinoid Cancer Foundation) aimed at patients, caregivers, and the broader neuroendocrine cancer community. The sessions are hosted by Rain Bennett. Watch 2026 SNMMI Patient Education Day May 31, 2026 Join us in Los Angeles on Sunday, May 31, for a dynamic patient education event, a collaboration between NorCal Carcinet and the Neuroendocrine Cancer Foundation, and in partnership with the Society of Nuclear Medicine and Molecular Imaging (SNMMI), a leading medical and scientific organization dedicated to advancing nuclear medicine and molecular imaging. Watch Regional Neuroendocrine Cancer Patient Conference in Atlanta, GA May 16, 2026 Join the Neuroendocrine Cancer Foundation (NCF) and Emory Winship Cancer Institute for a free, in-person educational conference designed specifically for people living with neuroendocrine cancer and their caregivers. This one-day program brings together leading experts from Emory University, the University of Alabama at Birmingham, and Vanderbilt University to provide practical, up-to-date information on the diagnosis and management of neuroendocrine cancer. Watch "Luncheon With The Experts" with Dr. Jaydira Del Rivero Apr 30, 2026 “Luncheon With The Experts” is a recurring educational outreach series (previously hosted by the Carcinoid Cancer Foundation) aimed at patients, caregivers, and the broader neuroendocrine cancer community. The sessions are hosted by Rain Bennett. Watch "Just Diagnosed With Neuroendocrine Cancer? What to Know and Understand" April 23, 2026 Being newly diagnosed with neuroendocrine cancer (NETs) can feel overwhelming. Many patients find themselves asking, “What exactly is neuroendocrine cancer, and how is it different from other cancers?” This webinar is designed to bring clarity, reassurance, and guidance during one of the most confusing stages of the NET journey. Watch "Luncheon With The Experts" with Dr. Boris G. Naraev Mar 26, 2026 “Luncheon With The Experts” is a recurring educational outreach series (previously hosted by the Carcinoid Cancer Foundation) aimed at patients, caregivers, and the broader neuroendocrine cancer community. The sessions are hosted by Rain Bennett. Watch "Novel Targeted Therapies in Neuroendocrine Cancers" Mar 9, 2026 Join us for a discussion of targeted therapies in neuroendocrine cancer, one of the fastest-growing areas of NET treatment. Unlike traditional chemotherapy, targeted therapies focus on specific pathways or features of cancer cells. Understanding how these treatments work can help patients feel more confident and informed when discussing options with their care team. Watch "The Latest in Neuroendocrine Cancer Clinical Trials" Feb 20, 2026 Join us for an overview of the latest clinical trials in neuroendocrine cancer with Dr. Heloisa Soares, a medical oncologist and physician-scientist at the Huntsman Cancer Institute (HCI) in Salt Lake City. Dr. Soares will walk through key neuroendocrine cancer clinical trials including what they are studying, what makes them exciting, and how they may shape future treatment options. She will also explain why clinical trials matter, how they benefit patients, and what to consider when exploring whether a trial might be right for you. Whether you’re a patient, caregiver, or simply trying to stay informed, this webinar will provide clear, practical insights to help you better understand emerging research and what it means for the neuroendocrine cancer community. Watch The Latest in the Management of Functional Neuroendocrine Cancers Jan 21, 2026 Join us for an easy-to-understand overview of functional neuroendocrine tumors (NETs) with Dr. Jaydira Del Rivero, a medical oncologist and endocrinologist at the National Cancer Institute. Functional NETs can cause the body to produce too many hormones, leading to challenging symptoms such as low blood sugar (often seen in insulinoma), high blood sugar (glucagonoma), carcinoid syndrome (excess serotonin), and other hormone-related issues and symptoms. Dr. Del Rivero will explain what these syndromes are, how they’re diagnosed, and the latest updates in treatment. She will also discuss conditions that can occur because of NETs or their treatments such as adrenal insufficiency. She will help patients understand why symptoms like hypoglycemia are more common in some NET types. Whether you’re a patient, caregiver, or simply want to better understand functional NETs, this webinar will offer practical, up-to-date information to help you feel more informed and empowered. Watch The Latest on Immunotherapy for Neuroendocrine Cancer Dec 11, 2025 Immunotherapy is an exciting and rapidly advancing area in the treatment of neuroendocrine cancer. Join Dr. Aman Chauhan, medical oncologist at the University of Miami Sylvester Cancer Center, as he discusses the latest developments in immunotherapy for NETs. This webinar will cover current standard-of-care treatments as well as cutting-edge clinical trials involving DLL3-targeted therapies, oncolytic viruses, CAR T-cell therapy, and combination approaches. Whether you’re newly diagnosed or exploring new treatment options, this session will help you better understand the evolving landscape of immunotherapy in neuroendocrine cancer. Event Page NCF Regional NET Patient Educational Event Nov 9, 2025 Join the Neuroendocrine Cancer Foundation and the Sylvester Comprehensive Cancer Center, part of UHealth – University of Miami Health System, in Miami, Florida, on Sunday, November 9th, from 8:30 am - 4:30 pm. More Info Coping With Neuroendocrine Cancer: Managing Distress, Worry & Grief Oct 28, 2025 A neuroendocrine cancer diagnosis can bring emotional, mental, and psychological challenges that are just as difficult as the physical ones. Join licensed clinical psychologist Dr. Karen Kersting from the Medical College of Wisconsin for a supportive discussion on Coping with Neuroendocrine Cancer: Managing Distress, Worry & Grief. She will offer insights and practical strategies to help patients and caregivers navigate the full emotional and psychological impact of living with NETs. Event Page Understanding Alpha & the Evolving PRRT Landscape Sep 22, 2025 The field of PRRT (Peptide Receptor Radionuclide Therapy) is evolving rapidly, and patients are hearing more about new developments like alpha therapies, the recent NETTER-2 and COMPETE trial results, and other advances. Join medical oncologist Dr. Udhayvir Singh Grewal from the Winship Cancer Institute of Emory University as he breaks down what these changes mean for people living with neuroendocrine cancer. This webinar will help patients and caregivers make sense of emerging research and therapies—and what they may mean for the future of NET treatment. Event Page Nutrition & Diet Considerations for NETs Aug 26, 2025 Nutrition can play a key role in living well with neuroendocrine cancer (neuroendocrine tumors or NETs). Join NET dietitian Meghan Laszlo for an informative session on nutrition and diet considerations for people living with neuroendocrine cancer. Event Page Living with NET: The Patient Perspective July 10, 2025 Join us for an open and honest conversation with four individuals living with neuroendocrine cancer as they share the realities of navigating life with an uncommon cancer. Event Page 2025 NCF Neuroendocrine Cancer Patient Conference June 14, 2025 Our 2025 NCF Neuroendocrine Tumor Patient Conference is designed for neuroendocrine cancer (NET or neuroendocrine tumor) patients and caregivers to deepen your understanding of NETs. Event Page NCF Regional NET Patient Educational Event May 17, 2025 The Neuroendocrine Cancer Foundation is hosting an in-person Neuroendocrine Cancer Educational Event for patients and caregivers in Santa Monica, California on Saturday, May 17th, from 3:45 -7:30 PM. Read the Event Blogpost "Evolving Management of Carcinoid Heart Disease: What We Know & What's New" April 29, 2025 Learn from Cardiologist and Congenital Heart Disease Specialist, Dr. Prashanth Venkatesh from Cedars-Sinai Smidt Heart Institute in a virtual educational event on carcinoid heart disease. Dr. Venkatesh demystifies the topic and shares the latest developments in its diagnosis and treatment, including a novel minimally invasive approach to replace heart valves damaged by carcinoid heart disease. Event Page "Understanding Treatments for Neuroendocrine Tumors and Rationale for Sequencing of Therapy" April 1, 2025 Learn from internationally-renowned neuroendocrine cancer expert Dr. Edward Wolin in a discussion on the latest in neuroendocrine tumor treatments and understanding how to sequence them. Dr. Wolin has pioneered many of the NET treatments including somatostatin analogues (SSAs, sandostatin and octreotide), mTOR inhibitors (i.e. everolimus), anti-angiogenic drugs (i.e. cabozantinib), and peptide receptor radiotherapy (PRRT, i.e. Lutathera). Listen to this insightful presentation and live question and answer session. Event Page NCF Regional NET Patient Educational Event March 29, 2025 The Neuroendocrine Cancer Foundation is hosting an in-person NET Educational Event for patients and caregivers in Tucson, Arizona on Saturday, March 29th, from 1:30-6:00 PM. Read the Event Blogpost "PRRT Nurse's Perspective: What to Expect with PRRT" March 7, 2025 Learn about PRRT from UCLA's Lead PRRT Nurse Linda Gardner. She addresses common questions about what to expect before, during, and after the treatment, as well as concerns about radiation safety. Event Page "Deciphering Genetics & Genomics in Neuroendocrine Cancers" with Dr. Kimberly Perez Feb 7, 2025 Learn the latest in genetics and genomics for neuroendocrine cancers from medical oncologist Dr. Kimberly Perez from Dana Farber Cancer Institute (DFCI) in Boston, Massachusetts. Dr. Perez has expertise in hereditary cancer syndromes and deciphers the topics of genetics and genomics. Event Page "Understanding GI NETs Found on Endoscopy: Gastric, Duodenal, Colon & Rectal" with Dr. David Metz Jan 28, 2025 Learn from renowned Neuroendocrinologist Dr. David Metz, who discusses neuroendocrine tumors (NETs) found on endoscopy, including gastric, duodenal, colon and rectal NETs. Dr. Metz discusses which NETs can be found on endoscopies and how they are managed and treated. Event Page Comprehensive Guide to Lung Neuroendocrine Cancers: From Typical Carcinoids to Small Cell Lung Cancer (SCLC) Tuesday, Dec 10, 2024 Learn all about lung neuroendocrine cancers from neuroendocrine cancer expert Dr. Aman Chauhan, leader of the Neuroendocrine Tumor Program and Co-Director of the Theragnostic Program at the Sylvester Comprehensive Cancer Center, University of Miami. Dr. Chauhan will give a comprehensive guide to lung neuroendocrine cancers ranging from typical carcinoids to small cell lung cancer. Event Page Palliative Care for Neuroendocrine Cancer Thursday, Nov 14, 2024 Learn about Palliative Care: what it is, what it is not, and how it may help those affected by neuroendocrine cancer. Dr. Chandana Banerjee, palliative care and hospice specialist from the City of Hope Cancer Center in Los Angeles, demystifies these topics. Event Page 2024 NET Cancer Day Symposium Saturday, November 9, 2024 Celebrate with us at the 2024 LACNETS NET Cancer Day Symposium in Santa Monica, California on Saturday, November 9th from 8:30 am - 4:30 pm. Event Page Evolving Management of NET Liver Metastases Friday, October 18, 2024 Hear the renowned liver and pancreas surgeon, Dr. Gagandeep “Gaugs” Singh, discuss the evolving algorithms in managing NET liver metastases. Dr. Singh, Chief of Surgical Oncology at City of Hope® Cancer Center in Phoenix, asks the question of whether it is prudent to be aggressive surgically or if it is all about timing and strategy. Regional NET Patient Education Conference Saturday, September 21, 2024 LACNETS is hosting an in-person NET Educational Event for patients and caregivers in Minneapolis, Minnesota, on Saturday, September 21st, from 1:30-5:00 PM. This event was not live-streamed or recorded. Meet the Expert: Dr. Eric Liu Saturday, August 17, 2024 Join LACNETS in Denver, Colorado for an in-person event. Meet NET expert Dr. Eric Liu who will give a broad survey of NET from diagnosis to treatment and philosophy. Engage in an interactive question and answer session with Dr. Liu. It’s a wonderful opportunity to learn, advocate and connect in-person with a NET expert and fellow NET patients and caregivers. 2024 LACNETS Neuroendocrine Tumor Patient Conference Saturday, June 15, 2024 Join us for the biggest LACNETS event of the year featuring more than ten NET experts. This year's theme is Deepening Your Understanding of NETs. Event Page High Grade Neuroendocrine Neoplasms & Small Cell Lung Cancer Tuesday, May 7, 2024 Learn about the latest in high grade neuroendocrine neoplasms and small cell lung cancer with medical oncologist Dr. Aman Chauhan, Leader of the Neuroendocrine Tumor Program and Co-Director of the Theragnostic Program at the Sylvester Comprehensive Cancer Center, University of Miami. 2024 Updates: Neuroendocrine Cancer Clinical Trials Thursday, April 25, 2024 Learn about the latest in clinical trials for neuroendocrine cancer with NET expert Dr. Heloisa Soares, a medical oncologist at the Huntsman Cancer Institute (HCI) at the University of Utah. TKIs: Tyrosine Kinase Inhibitors & Neuroendocrine Tumors Friday, Mar 29, 2024 Learn about Tyrosine Kinase Inhibitors (TKIs), what they are and how they work with NET expert Dr. Jennifer Chan. Dr. Chan is the Vice President of the North American Neuroendocrine Tumor Society (NANETS) and the principal investigator of the CABINET trial. Hear the positive findings from that TKI study using Cabozantinib. She discusses the latest in TKI treatments and how they may be a possible treatment option for many NET patients. LACNETS Educational Event Feb 14, 2024 Join us to learn about Carcinoid Heart Disease from Cardiologist Dr. S. Allen Luis at the Mayo Clinic in Rochester, MN. He will describe the cause and symptoms of carcinoid heart disease and discuss diagnosis, treatment and surveillance. LACNETS Educational Event "PRRT: What We Know, Special Considerations & Clinical Trials" with Dr. Jonathan Strosberg January 11, 2024 Join us on Thursday, January 11th at 9:30 AM Pacific to learn the latest on PRRT with NET expert Dr. Jonathan Strosberg. Dr. Strosberg was the principal investigator of the NETTER-1 study which led to the FDA approval of Lutathera and has authored numerous articles on PRRT. He will discuss the latest in PRRT, including special considerations and current clinical trials. LACNETS Educational Event "Minimally Invasive Treatments for Neuroendocrine Liver Metastases" with Dr. Yilun Koethe Dec 9, 2023 Join us to learn more about minimally invasive liver-directed therapies targeting liver metastases with interventional radiologist Dr. Koethe. She discusses ablations including the recently approved histotripsy and embolizations including bland, chemo, and radioembolization. LACNETS Educational Event "Symptoms Management" with Dr. David Metz Oct 10, 2023 Join LACNETS to hear Neuroendocrinologist Dr. David Metz from University of Pennsylvania discuss symptom management. The presentation will cover carcinoid syndrome, pancreatic enzymes, bile acid secretion, and short bowel syndrome. He will explain current treatments, supplements, and diets that might be helpful to control NET-related symptoms. LACNETS Educational Event "Navigating Clinical Trials: Expectations Vs. Realities" with Taymeyah Al-Toubah, MPH Aug 19, 2023 Hear Taymeyah Al-Toubah, MPH, Senior Research Project Manager at the Neuroendocrine Tumor Program of Moffitt Cancer Center. LACNETS Educational Event "Surgery: The What, Where & When" with Dr. Eric Liu July 7, 2023 Hear NET expert Dr. Eric Liu of Rocky Mountain Cancer Centers discuss “Surgery: The What, Where & When.” 2023 LACNETS Annual NET Patient Conference June 17, 2023 Watch our biggest event of the year with 12 NET experts from North America. WATCH NOW LACNETS E ducational Event Topic: High Grade Neuroendocrine Neoplasms (NEN) May 4, 2023 Join LACNETS on May 4th for an educational event dedicated to high grade neuroendocrine neoplasms (NENs). Medical oncologist Dr. Jason Starr from Mayo Clinic in Jacksonville, Florida, will discuss the management and treatment of high grade NENs, including the latest updates and clinical trials. LACNETS Educational Event: "What's New in PRRT" April 14, 2023 Join Dr. Amir Iravani, a Nuclear Medicine Physician and Theranostics Director at Fred Hutchinson Cancer Center, to hear the latest on Peptide Receptor Radionuclide Therapy (PRRT). Better understand the difference between beta and alpha PRRT, current trials and updates on PRRT for Lung NET, adolescents and dosimetry. LACNETS Educational Event: "Update on NET Clinical Trials" March 10 , 2023 Join Dr. Heloisa Soares, a medical oncologist at the Huntsman Cancer Institute (HCI) at the University of Utah, to hear the latest in NET clinical trials. LACNETS Educational Event: "Genetics of NET: Do I Need Genetic Testing?" Tuesday, February 7 , 2023 Do I need genetic testing? Do my family members need to be tested? What does genetic testing entail? What genetic mutations are possible and what does it mean for my family if I carry a mutation? Join Genetic Counselor Samantha Greenberg of University of Texas, Southwestern for a discussion about genetic testing for NETs. LACNETS Educational Event : "Novel Translational Research for Metastatic NET Patients at the NCI" Friday, January 27, 2023 Join LACNETS for this special educational event. What if you could both undergo surgery for your metastatic disease and also donate your liver tumor to find a cure for NET? Learn how you can contribute to NET research. The NET team at the National Cancer Institute (NCI) will give us a behind-the-scenes look at their innovative NET research. Be inspired by their hard work and dedication to the NET community. LACNETS Educational Event: Focus on Pheochromocytoma/Paraganglioma Wednesday, January 11, 2023 Join LACNETS for a unique webinar with a live presentation of three pheochromocytoma and paraganglioma (PPGL) cases and an engaging panel discussion with experts Dr. Jaydira Del Rivero, Dr. Erik Mittra, and Dr. Karel Pacak. Click here for our video library for more educational videos

<< Go back to the Podcast page EPISODE 48 - NEN TREATMENTS: FOCUS ON DLL3 Download a Transcript of this Episode >>> ABOUT THIS EPISODE DLL3 is emerging as a promising new target for neuroendocrine cancers. In this episode, Dr. Rohit Thummalapalli, medical oncologist at Memorial Sloan Kettering Cancer Center, explains what DLL3 is, how it works, who might benefit, and what current clinical trials are teaching us. He breaks down the science, treatment options, and future directions in a way that is clear, approachable, and designed to help patients and families better understand this developing area of care. MEET DR. ROHIT THUMMALAPALLI Rohit Thummalapalli is a gastrointestinal medical oncologist and assistant attending physician at Memorial Sloan Kettering Cancer Center specializing in clinical care and research in patients with neuroendocrine and biliary tract cancers. Originally from Florida, Dr. Thummalapalli completed medical training at Harvard and Johns Hopkins before arriving at MSK as a medical oncology fellow in 2021, and started on faculty in 2024. TOP TEN QUESTIONS: Understanding the Basics What is immunotherapy? How does immunotherapy work? What is DLL3? How does it work in the context of neuroendocrine cancer? How is DLL-targeted therapy similar to or different from other types of immunotherapy? Is there evidence that one works better than another? Indications, Use, Access & Availability When is DLL3 used in neuroendocrine cancers? What types of neuroendocrine cancer might express DLL3? How does someone know if this is a potential treatment option for them? c. At what point in a patient’s treatment journey might DLL3 be considered? d. How and where DLL3 is available for neuroendocrine cancer patients? What are other ways, if any, to access DLL3? Testing for DLL3 Expression How does someone find out if their tumors express DLL3 receptors? How & where is DLL3 expression tested? It it tested through tissue samples, imaging, or something else? Is there a minimal level of DLL3 expression that is required to receive the treatment? (Does the threshold vary by trial?) Does the level of DLL3 expression differ by institution? Does the level of DLL3 expression predict how well someone might respond to treatment? Can the tumor expression of DLL3 vary from tumor to tumor? Can it vary over time, meaning can tumors gain or lose expression? Do you measure the DLL3 expression following treatment? Treatment Considerations How effective is DLL3-targeted therapy in neuroendocrine cancers? What is the goal of treatment with DLL3 – shrinkage, stabilization, symptom relief? How long is it expected to work? How do you measure the response to DLL3 treatment? Can DLL3 be combined with other therapies? Decision-Making and Patient Counseling How do you decide when to offer DLL3 for someone with neuroendocrine cancer? What factors or prior treatments might make someone ineligible for DLL3 therapy? Could receiving DLL3 exclude a patient from other treatments or clinical trials? How do you counsel patients who are considering DLL3? What should they know about how the treatment is given, possible side effects, and what’s known (or unknown) about long-term safety? What should one expect in terms of frequency of visits, hospitalization and side effects? Can someone still work while receiving DLL3? Looking Ahead What are the key questions you hope to answer about DLL3 in the next year? What do you hope to learn over the next 3 to 5 years? RESOURCES LISTEN Neuroendocrine Cancer Foundation Podcast Episode 36: NEN Treatments: Focus on Immunotherapy EXPLORE Clinical Trials Guide: Immunotherapy READ Landscape of functional DLL3 expression in gastroenteropancreatic neuroendocrine neoplasms (GEP NENs) (May 28, 2025) Efficacy and safety of the DLL3/CD3 T-cell engager obrixtamig in patients with extrapulmonary neuroendocrine carcinomas with high or low DLL3 expression: Results from an ongoing phase I trial (May 28, 2025) Delta-Like Ligand 3 Expression and Functional Imaging in Gastroenteropancreatic Neuroendocrine Neoplasms - JCO Precision Oncology, November 20, 2025 WATCH Dr. Strosberg on Research Clarifying the Role of Obrixtamig in SCLC and Other Neuroendocrine Cancers (May 5, 2025) Obrixtamig Could Broaden the Reach of DLL3/CD3-Targeted BiTEs in Small Cell Lung and Other Neuroendocrine Cancers (May 5, 2025) IMMUNOTHERAPY-BASED DLL3-TARGETED CLINICAL TRIALS Tarlatamab in DLL3-Expressing Tumors Including Neuroendocrine Neoplasms https://www.youtube.com/watch?v=HJCZzlD_kq8 NOVEL NON-IMMUNOTHERAPY-BASED DLL3-TARGETED CLINICAL TRIALS Immuno-PET Imaging of Neuroendocrine Tumors Using 89Zr-DFO-SC16.56, a DLL3-targeting Monoclonal Antibody A Study of ZL-1310 in Participants With Selected Solid Tumors https://www.youtube.com/watch?v=RQF3krrFx_g 225Ac-ABD147 to Establish Optimal Dose in Patients With SCLC and LCNEC of the Lung That Previously Received Platinum-based Chemotherapy https://www.youtube.com/watch?v=PDR0flgpAXE DISCLAIMER The Neuroendocrine Cancer Foundation Podcasts are created for educational purposes only and do not substitute for medical advice. The views shared in this Podcast are the personal opinions of the experts and do not necessarily reflect the views of the Neuroendocrine Cancer Foundation. Please contact your medical team with questions or concerns about your individual care or treatment. THANK YOU TO OUR SPONSORS

< Go Back to the Resource Guide CARCINOID HEART DISEASE WATCH https://www.youtube.com/watch?v=jU1HE38G8JQ Learn from Cardiologist and Congenital Heart Disease Specialist, Dr. Prashanth Venkatesh from Cedars-Sinai Smidt Heart Institute in a virtual educational event on carcinoid heart disease. Dr. Venkatesh demystifies the topic and shares the latest developments in its diagnosis and treatment, including a novel minimally invasive approach to replace heart valves damaged by carcinoid heart disease. https://www.youtube.com/watch?v=DcewKhYm8uY Learn about Carcinoid Heart Disease from Cardiologist Dr. S. Allen Luis at the Mayo Clinic in Rochester, MN. He will describe the cause and symptoms of carcinoid heart disease and discuss diagnosis, treatment and surveillance. https://www.youtube.com/watch?v=Y5PGL8-kFR4 Guests: Juan A. Crestanello, MD and Thor R. Halfdanarson, MD Host: S. Allen Luis, MBBS, PhD Join Mayo Clinic Cardiologist S. Allen Luis, M.B.B.S., Ph.D., surgeon Juan A. Crestanello, M.D. and oncologist Thor R. Halfdanarson, M.D. for up-to-date knowledge and information on Carcinoid Heart Disease. Recognize the natural history of patients with carcinoid heart disease. Identify treatment strategies for patients with metastatic neuroendocrine tumors and its impact on the heart Identify the medical and surgical treatment of patients with carcinoid heart disease. PATIENT STORIES https://www.youtube.com/watch?v=4TU4WMGd4lc Watch Jesse & Ellen share their story of living with Carcinoid Heart Disease. https://www.youtube.com/watch?list=PLPAgUIq-85n9gMW_Majhts3lqzoIaIQbx&v=tMBDhGT5lmI Watch Gwendolyn’s story of living with metastatic NET and Carcinoid Heart Disease. LISTEN What is Carcinoid Heart Disease (CHD)? Which NET patients develop CHD? Retired cardiologist and carcinoid heart disease specialist Dr. Jerome Zacks provides an overview of CHD and describes the appropriate screening, diagnosis, and treatment. Visit the Podcast Episode 43 webpage for more information and resources. READ Davar et al (2017). "Diagnosing and Managing Carcinoid Heart Disease in Patients With Neuroendocrine Tumors: An Expert Statement". J Am Coll Cardiol.; 69 (10) 1288–1304 Jin et al (2021). "Carcinoid Heart Disease: Pathophysiology, Pathology, Clinical Manifestations, and Management". Cardiology;146:65–73 Ram et al (2019). "Carcinoid Heart Disease:Review of Current Knowledge". Texas Heart Institute Journal February 2019, Vol. 46, No. 1

Join NCF for Mar2024. Explore event details, dates, times, and discover opportunities to connect, learn, and get involved. < Back to the upcoming events page https://www.youtube.com/watch?v=OCtGElKt_J4 Learn about Tyrosine Kinase Inhibitors (TKIs), what they are and how they work, with NET expert Dr. Jennifer Chan. Dr. Chan is the Vice President of the North American Neuroendocrine Tumor Society (NANETS) and the principal investigator of the CABINET trial. Hear the positive findings from that TKI study using Cabozantinib. She discusses the latest in TKI treatments and how they may be a possible treatment option for many NET patients. ABOUT DR. JENNIFER CHAN Jennifer Chan, MD, MPH is an Associate Professor of Medicine at Harvard Medical School and Institute Physician in the Division of Medical Oncology at Dana-Farber Cancer Institute in Boston, MA. She focuses her clinical practice on the care of patients with neuroendocrine tumors and gastrointestinal cancers. Dr. Chan is the Director of the Program in Neuroendocrine and Carcinoid Tumors and Clinical Director for the Gastrointestinal Cancer Center at the Dana-Farber/Brigham and Women's Cancer Center. She has been the principal investigator of multiple clinical trials investigating novel therapies for neuroendocrine tumors and has been involved in studies examining factors associated with clinical outcomes in patients with neuroendocrine tumors. Dr. Chan is a past chair of the Guidelines Committee of the North American Neuroendocrine Tumor Society (NANETS) and the current Vice President of NANETS. She serves on the National Comprehensive Center Network (NCCN) Neuroendocrine Tumors Guidelines Panel. Dr. Chan is a member of the Neuroendocrine Tumor Taskforce of the National Cancer Institute and the Board of Directors of NANETS. SPONSORS The information provided is for educational purposes only and does not substitute for medical advice. Talk to your medical team if you have any questions or concerns about your individual care and treatment. The opinions expressed in this program are those of the speakers and do not represent the opinion of LACNETS.